MaxCyte
MaxCyte (NASDAQ: MXCT) develops Flow Electroporation-based non-viral cell engineering instruments and consumables, serving cell and gene therapy developers, biologics producers, and academic researchers worldwide through direct sales, a Strategic Platform Licensing model, and the SeQure Dx gene editing risk assessment services acquired in 2025.
- Company typePublic
- Founded1999
- HeadquartersGaithersburg, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What MaxCyte does
MaxCyte, Inc. (NASDAQ: MXCT) is a publicly traded life sciences tools company founded in 1999 and headquartered in Rockville, Maryland. The company develops and commercializes Flow Electroporation technology, a non-viral cell engineering method that uses controlled electrical pulses to transiently permeabilize cell membranes and deliver nucleic acids, proteins, and other molecules into eukaryotic cells. Its ExPERT platform spans five instruments covering the full development continuum: the DTx (96-well discovery), ATx (small-to-mid scale research), STx (protein and vaccine production), GTx (cGMP clinical manufacturing), and VLx (200-billion-cell gram-scale production). The instruments share common consumables and protocols, enabling seamless scale-up without process reoptimization, and are sold alongside proprietary processing assemblies and buffers.
MaxCyte monetizes through three streams: (1) hardware and consumable sales of ExPERT instruments and proprietary disposables to academic, biotech, and pharmaceutical customers; (2) the Strategic Platform Licensing (SPL) program, a milestone-based licensing model under which cell and gene therapy developers gain access to the electroporation platform, with 32+ active SPL partners including CRISPR Therapeutics and Vertex Pharmaceuticals (whose CASGEVY became the first FDA-approved non-viral CRISPR-based therapy using MaxCyte's technology); and (3) SeQure Dx services for gene editing off-target and on-target risk assessment, following the January 2025 acquisition of SeQure Dx. The platform is supported by an FDA Master File continuously maintained since 2002, ISO 9001 manufacturing, and 21 CFR Part 11-compliant instruments.
The company serves cell and gene therapy developers (its primary segment), protein and biologics producers, drug discovery and screening groups, and vaccine/mRNA therapeutics developers. Distribution combines direct enterprise sales in the US with a network of regional distributors across Asia-Pacific, Europe, and Israel. FY2025 revenue was $33.0M (down 15% YoY), with $155.6M in cash and a $16M+ reduction in annual cash burn; 2026 guidance is $30-32M as core instrument revenue continues to face headwinds offset by 62% growth in SPL program revenue.
MaxCyte firmographics
Firmographics- Name
- MaxCyte
- Legal name
- MaxCyte, Inc.
- Website
- https://maxcyte.com
- Company type
- Public
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- MaxCyte (NASDAQ: MXCT) develops Flow Electroporation-based non-viral cell engineering instruments and consumables, serving cell and gene therapy developers, biologics producers, and academic researchers worldwide through direct sales, a Strategic Platform Licensing model, and the SeQure Dx gene editing risk assessment services acquired in 2025.
- Ownership category
- akta.pro rank
MaxCyte industry classification
Industry- Product category
- Cell Engineering Instrumentation and Services
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
- akta.pro secondary industries
- Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services (HLAAACAM), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
Keywords
Where MaxCyte is headquartered
LocationHeadquarters
- HQ city
- Gaithersburg
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MaxCyte business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Electroporation Instruments and Consumables: Sale of electroporation instruments (ExPERT DTx, ATx, STx, GTx, VLx) and associated consumables (Processing Assemblies, Reagents, Buffers) for cell engineering applications. Instruments range from research-use-only to GMP-compliant manufacturing systems.
- Strategic Platform Licensing (SPL): Partnership-driven licensing model providing access to MaxCyte's electroporation technology. The licensing model is structured to take effect after partners reach clinical and commercialization milestones, creating a win-win approach. Revenue from SPL programs grew 62% to $3.4M in Q1 2026.
- SeQure Gene Editing Services: Gene editing risk assessment services including screening, nomination, and confirmation assays for off-target and on-target editing characterization. Supports IND submissions and regulatory compliance for cell and gene therapy developers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | One time/ perpetual license | Electroporation instruments (DTx, ATx, STx, GTx, VLx) with varying scale capabilities |
| Unit Pricing | Pay-as-you-go | Processing assemblies and reagents |
| Other | Multi-year contract | SeQure gene editing risk assessment services |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
MaxCyte product offering
Product offeringCore offering
MaxCyte develops and commercializes non-viral Flow Electroporation technology for cell engineering, offering a portfolio of five ExPERT instruments (DTx, ATx, STx, GTx, VLx) that scale from discovery through GMP manufacturing. The company sells proprietary processing assemblies, buffers, and reagents as consumables, and provides gene editing risk assessment services through its SeQure sub-brand. Customers include biotech firms, biopharmaceutical companies, and academic institutions developing cell therapies, gene therapies, vaccines, and biologics.
Product overview
MaxCyte offers the ExPERT platform, a family of electroporation instruments designed for non-viral cell engineering across the full development continuum from discovery through commercial manufacturing. The platform comprises five distinct instruments: DTx (96-well high-throughput for discovery), ATx (small-to-medium scale R&D), STx (protein/vaccine production), GTx (cGMP clinical manufacturing), and VLx (gram-scale protein production). These instruments share common consumables and protocols, enabling seamless scale-up without reoptimization. The SeQure sub-brand provides comprehensive gene editing risk assessment services across three tiers—screening (Guide Profiler, Guide Select), nomination (ONE-seq, DEUX-seq, GUIDE-seq), and confirmation (Amplicon-seq, SAFER Detection)—addressing FDA guidance requirements for off-target and structural rearrangement assessment in cell and gene therapy development.
Differentiator
Problem solved
Functional benefit
Brands
- ExPERT: Electroporation technology platform for cell engineering across research and manufacturing scales
- SeQure
- ExPERT DTx
- Flow Electroporation
Products and services
- ExPERT DTx High-throughput 96-well electroporation platform for research and drug discovery applications, processing up to 96 samples in a single three-minute run using detachable 8-well strip assemblies. Enables customizable protocols for diverse cell and cargo combinations with high cell viability and direct scalability to cGMP-compliant manufacturing across the ExPERT platform. Targeted at discovery and screening researchers.
- ExPERT ATx Small to medium scale electroporation instrument for research transfection, supporting 75,000 to 700 million cells with high efficiency and viability. Designed for research laboratories conducting cell therapy R&D and gene editing studies with reliable, reproducible protocols.
- ExPERT STx Scalable transfection system for complex proteins, vaccines, and biologics production. Supports 100,000 to 20 billion cells with efficient, reproducible transient transfection that can delay the need for stable cell line development. Used by researchers and process developers for antibody and vaccine production.
- ExPERT GTx Clinically validated, cGMP-compliant Flow Electroporation system for manufacturing of cell-based therapies, capable of transfecting up to 20 billion cells. Marketed as the only clinically validated electroporator developed specifically for cell therapy manufacturing, used in clinical and commercial cell and gene therapy production.
- ExPERT VLx High-capacity electroporation system for gram-scale protein production, capable of transfecting 200 billion cells in less than 30 minutes. Enables seamless transition from discovery to manufacturing with high throughput for antibody, biologics, and vaccine production.
- Processing Assemblies Range of consumable devices providing options for project scale and throughput from discovery through cGMP manufacturing. Includes multiple volume formats (96-well strips, static assemblies, flow electroporation assemblies for closed-system processing) used with ExPERT instruments.
- Electroporation Buffer Proprietary electroporation buffer available in multiple formats including GMP and closed-bag configurations. Animal-derived component free, 0.1 µm filtered, meeting technical, sterility, and endotoxin specifications. Compatible with all MaxCyte ExPERT instrument platforms.
- SeQure Guide Profiler In silico screening assay enabling rapid evaluation of potential off-target effects associated with gene editing tools. Allows researchers to screen sgRNAs to understand on-target efficacy and off-target editing risks during early discovery and target validation.
- SeQure Guide Select Biochemical screening assay for screening multiple guide RNAs in parallel. Variant-aware searching within a limited search space enables high-powered, low-cost risk assessment for guide RNA selection and program prioritization in gene editing programs.
- SeQure ONE-seq Gold standard nomination assay for population-scale, variant-aware off-target detection. Combines candidate off-target enumeration, enrichment, and in vitro cutting with deep sequencing for high-sensitivity detection of low-frequency off-target events in gene editing programs.
- SeQure DEUX-seq Biochemical, orthogonal nomination assay that validates and reinforces ONE-seq findings. Leverages in vitro cutting of genomic DNA followed by deep sequencing to determine potential off-target effects of gene editing tools.
- SeQure GUIDE-seq Cell-based, orthogonal nomination assay that utilizes co-transfection of a DNA tag alongside gene editing tools to profile potential off-target effects in chosen cell types. Used by cell and gene therapy developers for IND-enabling risk assessment.
- SeQure Amplicon-seq Confirmation assay providing high-sensitivity confirmation of on- and off-target edits in gene-edited cell lines and tissues. Targeted amplicon sequencing guided by nomination assay results, supporting IND submissions for cell and gene therapies.
- SeQure SAFER Detection Confirmation assay confirming on-target, off-target, and homology-mediated structural rearrangements from gene editing. Addresses FDA expectations for structural rearrangement data to mitigate IND filing delays in cell and gene therapy programs.
Quantifiable outcome
- 2.4x increased cell viability and 1.4x higher gene expression compared to conventional systems in CAR-T manufacturing (VectorBuilder partnership data)
- +3 more outcomes
Companies that use MaxCyte
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
MaxCyte technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
MaxCyte partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- VectorBuildercoreStrategic partnership to co-develop next-generation gene delivery solution combining VectorBuilder's MiniVec plasmid system with MaxCyte's Flow Electroporation technology for ex vivo cell engineering applications. Preliminary CAR-T manufacturing data demonstrated 2.4x increased cell viability and 1.4x higher gene expression compared to conventional systems, addressing critical challenges in safety and manufacturability for cell therapies.
- Adicet BiocoreStrategic Platform Licensing agreement for development of gamma delta T cell therapy programs. MaxCyte's Flow Electroporation technology will support gene editing in allogeneic T cell therapy manufacturing.
- Anocca ABcoreStrategic Platform Licensing agreement to advance TCR-T cell therapy pipeline. MaxCyte's Flow Electroporation technology will support non-viral gene editing in manufacture of Anocca's TCR-T cell therapies.
- Ori BiotechcoreCollaboration to improve manufacturing efficiencies and broaden adoption of autologous cellular therapies. Integration of MaxCyte's ExPERT Electroporation platform with Ori's IRO manufacturing system aims to improve gene-edited T cell yield, shorten manufacturing timelines, and support seamless path from R&D to GMP production.
- Cell and Gene Therapy Developers (Academic and Industry Partners)coreMaxCyte partners with leading academic institutions, translational centers, and biopharmaceutical companies worldwide for cell and gene therapy development. The partnership-driven licensing model provides scalable solutions from discovery to commercialization, with expert support and proven scalability. Company has collaborated in 35 clinical trials with partners in pharma and biotech developing treatments for cancer, CNS disorders, and rare genetic diseases.
Scale indicators9 records
Recent moves8 records
Expansion highlights6 records
MaxCyte competitors and assessment
Company assessmentDirect peers
- Thermo Fisher Scientific: Thermo Fisher offers the Neon NxT electroporation system and BTX electroporation/cell fusion instruments, directly competing with MaxCyte's ExPERT platform for cell engineering market share among cell therapy developers and academic researchers.
- Bio-Rad Laboratories: Bio-Rad's Gene Pulser and electroporation product lines compete directly with MaxCyte's Flow Electroporation technology across research and cell therapy manufacturing applications, serving similar biopharma and academic customers.
- Harvard Bioscience (BTX): Harvard Bioscience's BTX division offers electroporation and electrofusion instruments for cell engineering, competing directly with MaxCyte in transfection equipment for research and clinical cell therapy manufacturing.
- BEX Co., Ltd. BEX is a Japanese manufacturer of electroporation equipment (including the CUY21 series) used for in vivo and ex vivo transfection, representing a regional direct competitor to MaxCyte in gene delivery instrumentation.
Emerging players
- Miltenyi Biotec: Miltenyi Biotec offers a broad portfolio of cell therapy tools and instruments (including the CliniMACS platform), competing with MaxCyte for share among CAR-T and gene-edited cell therapy developers through complementary rather than identical cell engineering modalities.
Broad incumbents
- Lonza Group: Lonza is a leading cell and gene therapy CDMO offering process development and GMP manufacturing services that compete with portions of MaxCyte's SPL offering, while also serving many of the same cell therapy developers as customers.
- Catalent: Catalent is a major cell therapy CDMO providing process development and GMP manufacturing services, overlapping with MaxCyte's enabling-tools positioning as a partner to cell therapy developers seeking manufacturing solutions.
- Sartorius AG: Sartorius provides bioprocessing equipment and cell therapy manufacturing solutions that compete in adjacent steps of the cell therapy workflow, serving many of the same biopharma customers with broader portfolios that include cell engineering alternatives.
- Cytiva (Danaher): Cytiva offers a broad portfolio of bioprocessing and cell therapy manufacturing equipment under Danaher, competing with MaxCyte at the manufacturing scale-up stage and serving overlapping cell therapy developer customers globally.
Others
- Agilent Technologies: Agilent provides life sciences instrumentation and analytical tools serving similar biopharma and academic research customers as MaxCyte, and recently hired MaxCyte's incoming CFO from its investor relations function, signaling overlap in talent markets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
MaxCyte social profiles
Digital presenceMaxCyte compliance and trust
Trust signalCompliance3 records
MaxCyte financial estimates
Financial estimateRevenue estimate
Valuation estimate
MaxCyte leadership team
Management profileNumber of profiles
Profiles6 records
MaxCyte subsidiaries and ownership
Company hierarchySubsidiaries1 record
MaxCyte funding detail
Funding detailFunding overview
Funding rounds8 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MaxCyte M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MaxCyte
What does MaxCyte do?
MaxCyte develops and commercializes non-viral Flow Electroporation technology for cell engineering, offering a portfolio of five ExPERT instruments (DTx, ATx, STx, GTx, VLx) that scale from discovery through GMP manufacturing. The company sells proprietary processing assemblies, buffers, and reagents as consumables, and provides gene editing risk assessment services through its SeQure sub-brand. Customers include biotech firms, biopharmaceutical companies, and academic institutions developing cell therapies, gene therapies, vaccines, and biologics.
Is MaxCyte a public or private company?
MaxCyte is a public company. It is classified as public and is currently operating.
When was MaxCyte founded?
MaxCyte was founded in 1999. It employs 101 to 250 people.
Where is MaxCyte based?
MaxCyte is headquartered in Gaithersburg, United States, in the North America region.
How does MaxCyte make money?
Three revenue lines are on record. Electroporation Instruments and Consumables are the primary driver. The others are strategic Platform Licensing (SPL) and seQure Gene Editing Services.
Who are MaxCyte's main competitors?
Direct peers on record are Thermo Fisher Scientific, Bio-Rad Laboratories, Harvard Bioscience (BTX) and BEX Co., Ltd.. Miltenyi Biotec is listed as an emerging player. Broad incumbents are Lonza Group, Catalent, Sartorius AG and Cytiva (Danaher). Agilent Technologies is listed as an others.
Does MaxCyte have an API?
No public API is recorded for MaxCyte.
What industry is MaxCyte in?
MaxCyte's product category is Cell Engineering Instrumentation and Services. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAACAM, Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services. Its NAICS code is 334510 and its SIC code is 3845.